Circio presents pre-clinical proof-of-concept data for its circVec gene therapy platform at the ASGCT 2024 meeting
· Two posters demonstrate in vivo superiority of circular RNA vs. linear mRNA-based expression and technical proof-of-concept for Circio´s ´remove-&-replace´ gene therapy format for the unmet medical need AATD · The posters were presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting 7-11 May in Baltimore, USAOslo, Norway, 13 May 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing circular RNA-based gene therapy, today announces that it has presented two posters that demonstrate in vivo proof-of-concept for its powerful and